1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
- Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin.
- 2008
- A Randomised Placebo Controlled Study With Melphalan/Prednisone Vs Melphalan/Prednisone/Thalidomide: Quality Of Life And Toxicity
- Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
- 2004
- Low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma
- Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma
- Early response predicts thalidomide efficiency in patients with advanced multiple myeloma
- 2003
- Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis.
- 2002
- Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor
- 2000
- A closed-chest pulmonary artery occlusion/reperfusion model in the pig: detection of experimental pulmonary embolism with MR angiography and perfusion MR imaging
- Perfusion magnetic resonance imaging of the lung: characterization of pneumonia and chronic obstructive pulmonary disease. A feasibility study